Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade.

Sinha, Debottam; Moseley, Philip; Lu, Xuehan; Wright, Quentin; Gabrielli, Brian; Frazer, Ian H; Cruz, Jazmina L G.

Afiliação

Sinha D; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Moseley P; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Lu X; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Wright Q; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Gabrielli B; Mater Research Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Frazer IH; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Cruz JLG; Faculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.

Cancers (Basel) ; 14(24)2022 Dec 13.

Article em En | MEDLINE | ID: mdl-36551637